Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

diaDexus licenses rights to testisin cancer target

Feb. 14, 2003

Debiopharm forms collaboration with Tulane University

Feb. 13, 2003

Lorus Therapeutics and NCI to evaluate GTI-2040 in phase II trials

Feb. 13, 2003

Echelon Biosciences awarded grant for cancer and diabetes research

Feb. 13, 2003

Aventis claims new KDR inhibitors obtained from natural source

Feb. 13, 2003

SuperGen submits second module of rolling NDA for Orathecin

Feb. 12, 2003

AstraZeneca submits MAA for Iressa for advanced NSCLC

Feb. 12, 2003

Transgene announces encouraging results from phase I oncology trials

Feb. 12, 2003

Clinical toxicity and pharmacokinetics determined for lead alkycycline

Feb. 11, 2003

Fludara receives E.U. approval as first-line treatment for B-CLL

Feb. 11, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...